Comparison of Efficacy of Pembrolizumab between Epstein-Barr VirusPositive and Negative Relapsed or Refractory Non-Hodgkin Lymphomas
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), realworld data about the efficacy of pembrolizumab in NHL patients are limited. Materials and Methods We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression. Results Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%). Conclusion Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.
Abstract
Purpose Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), realworld data about the efficacy of pembrolizumab in NHL patients are limited. Materials and Methods We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression. Results Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%). Conclusion Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.
참고문헌 (30)
- Mak V, "Survival of patients with peripheral T-cell lymphoma after first relapse or progression : spectrum of disease and rare long-term survivors", J Clin Oncol, 31, pp.1970~1976 (2013)
- Crump M, "Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study", Blood, 130, pp.1800~1808 (2017)
- Weber J, "Immune checkpoint proteins : a new therapeutic paradigm for cancer--preclinical background : CTLA-4 and PD-1blockade", Semin Oncol, 37, pp.430~439 (2010)
- Chen L, "Molecular mechanisms of T cell co-stimulation and co-inhibition", Nat Rev Immunol, 13, pp.227~242 (2013)
- Kwong YL, "PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK", T-cell lymphoma failing l-asparaginase, 2017, pp.129, 2437~2442
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Kim SJ, "Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer", T-cell lymphoma, nasal type: a multicentre, retrospective analysis, 2015, pp.2, e66~e74
- Dako North America, "PD-L1 IHC 22C3 pharmDx (package insert)" (2015), Dako North America
- Lai J, "Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer", T-cell lymphoma patient with multi-line resistance : a case report, 2017, pp.17, 507~
- Chan TS, "Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation : efficacy and safety", Ann Hematol, 95, pp.1913~1915 (2016)
- Zinzani PL, "Safety and tolerability of pembrolizumab in patients with relapsed", refractory primary mediastinal large B-cell lymphoma, 2017, pp.130, 267~270
- Nastoupil LJ, "High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma:interim results of an on open-label, phase II study", Hematol Oncol, 35(Suppl 2), pp.120~121 (2017)
- Chan TS, "Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma", Ann Hematol, 95, pp.1917~1918 (2016)
- Menter T, "Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas", Hum Pathol, 54, pp.17~24 (2016)
- Vranic S, "PD-L1 status in refractory lymphomas", PLoS One, 11, pp.e0166266~ (2016)
- Kiyasu J, "Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma", Blood, 126, pp.2193~2201 (2015)
- Roemer MG, "PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome", J Clin Oncol, 34, pp.2690~2697 (2016)
- Twa DD, "Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma", Blood, 123, pp.2062~2065 (2014)
- Chapuy B, "Targetable genetic features of primary testicular and primary central nervous system lymphomas", Blood, 127, pp.869~881 (2016)
- Four M, "PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival", Hematol Oncol, 35, pp.487~496 (2017)
- Jo JC, "Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK", T-cell lymphoma, nasal type, 2017, pp.96, 25~31
- Kim WY, "Expression of programmed cell death ligand 1(PD-L1)in advanced stage EBV-associated extranodal NK", T cell lymphoma is associated with better prognosis, 2016, pp.469, 581~590
- Ding W, "Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL", Blood, 129, pp.3419~3427 (2017)
- Chen BJ, "PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies", Clin Cancer Res, 19, pp.3462~3473 (2013)
- Roach C, "Development of a companion diagnostic PD-L1immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer", Appl Immunohistochem Mol Morphol, 24, pp.392~397 (2016)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Cheson BD, "Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy", Blood, 128, pp.2489~2496 (2016)
- Chan TS, "Low-dose pembrolizumab for relapsed", refractory Hodgkin lymphoma : high efficacy with minimal toxicity, 2017, pp.96, 647~651
- Armand P, "Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure", J Clin Oncol, 34, pp.3733~3739 (2016)
- Chen R, "Phase II study of the efficacy and safety of pembrolizumab for relapsed", refractory classic Hodgkin lymphoma, 2017, pp.35, 2125~2132